Ono Pharma developing new diagnostic for potential Opdivo patients

Japan's Ono Pharmaceutical is planning to develop a new diagnostic tool to determine whether more cancer patients will benefit from the cancer drug Opdivo. The company has put together a team of 6 researchers to ID cancer biomarkers; it has already found one marker that "determines how well a patient could respond to the drug." Opdivo was approved in Japan in 2014 for melanoma treatments and in 2015 for lung cancer. A Nikkei report said the company earned $21 million from Opdivo sales in 2014 and that a new diagnostic tool could increase sales. The approach differs from conventional treatments because it looks for patients with specific genetic codes, but this entails a "companion diagnostic" to ID benefits and side effects. Report

Suggested Articles

The FDA is bracing for drug and medical supply shortages in the U.S. as the COVID-19 outbreak from China continues to spread globally.

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.

A Chinese company's producing a remdesivir generic. Daiichi expects $18 million in Enhertu Q1 sales. Tecentriq becomes seventh PD-1/L1 to enter China.